BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 7, 2013
View Archived Issues
Merck & Co. provides pipeline overview in 2012 financial results
Read More
BTK inhibitors designed at Novartis
Read More
Novartis presents novel HDAC4 inhibitors
Read More
Novel platinum complexes developed by Chinese team
Read More
Cangene acquires rights to IB-1001
Read More
GSK supports AllTrials campaign
Read More
Mitsubishi Tanabe's in-house and out-licensed programs advance in third quarter of fiscal 2012
Read More
Oncotype DX Colon Cancer test can affect treatment recommendations and costs
Read More
Therapeutic cervical cancer vaccine eradicates established tumors in mice
Read More
Diagnostics for cancer developed by group of French researchers
Read More
The University of Bath designs agents for drug and alcohol abuse
Read More
Merck & Co. describes new Trk-A inhibitors
Read More
Ability Pharmaceuticals receives grant to develop lipid analogue therapeutic
Read More
Summit and Children's National Medical Center form biomarker collaboration for DMD
Read More
Autophagy-inducing peptide drug displays antiviral activity
Read More
GSK to advance GSK-2586184 into phase II studies
Read More
Regen BioPharma files IND for drug-refractory aplastic anemia therapeutic
Read More
Phase II trial investigates PC-SOD for idiopathic pulmonary fibrosis in Korea
Read More
Seikagaku begins phase II trial for SI-613 in Japan
Read More
Biogen acquires full rights to Tysabri
Read More
Astellas Pharma profiles pipeline progress of third quarter of fiscal 2012
Read More
Seattle Genetics begins two phase I trials of SGN-CD19A
Read More
First patient treated in phase I trial of GL-ONC1
Read More
Phase II study of Zybrestat plus Avastin passes interim toxicity analysis
Read More
Chugai seeks expanded Japanese approval for Herceptin
Read More